BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
McKesson
Deloitte
Cantor Fitzgerald
US Department of Justice
US Army
Argus Health
Julphar
Accenture
Johnson and Johnson

Generated: January 20, 2018

DrugPatentWatch Database Preview

Gabapentin enacarbil - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for gabapentin enacarbil and what is the scope of gabapentin enacarbil patent protection?

Gabapentin enacarbil
is the generic ingredient in one branded drug marketed by Arbor Pharms Llc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Gabapentin enacarbil has one hundred and forty-seven patent family members in twenty-five countries.

There are twenty-eight drug master file entries for gabapentin enacarbil. Two suppliers are listed for this compound.
Summary for gabapentin enacarbil
Pharmacology for gabapentin enacarbil

US Patents and Regulatory Information for gabapentin enacarbil

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for gabapentin enacarbil

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,423,169 Methods for synthesis of acyloxyalkyl derivatives of GABA analogs ➤ Subscribe
8,906,412 GABA analog prodrug sustained release oral dosage forms ➤ Subscribe
6,833,140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity ➤ Subscribe
8,367,722 Methods of using prodrugs of pregabalin ➤ Subscribe
6,972,341 Prodrugs of GABA analogs, compositions and uses thereof ➤ Subscribe
7,790,708 Prodrugs of GABA analogs, compositions and uses thereof ➤ Subscribe
7,232,924 Methods for synthesis of acyloxyalkyl derivatives of GABA analogs ➤ Subscribe
7,186,855 Prodrugs of GABA analogs, compositions and uses thereof ➤ Subscribe
9,150,503 Crystalline form of .gamma.-aminobutyric acid analog ➤ Subscribe
8,168,623 Prodrugs of GABA analogs, compositions and uses thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for gabapentin enacarbil

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Medtronic
Dow
Merck
Cantor Fitzgerald
McKesson
Farmers Insurance
Accenture
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot